Hepatitis C Virus Core Antigen Testing: Role in Diagnosis, Disease Monitoring and Treatment

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2014 Jun 20

PMID 24944462

Citations 25

Authors

Hans L Tillmann

Affiliations

Soon will be listed here.

Abstract

While hepatitis B virus (HBV) screening relies on hepatitis B surface antigen to confirm HBV infection since the early days of hepatitis B disease management, hepatitis C virus (HCV) infection screening is based on anti-HCV testing which does not discriminate active from past infection. Thus to confirm infection HCV RNA testing has been required; recently a HCV core antigen assay became widely commercially available which could serve to confirm infection. That assay is less sensitive than current HCV RNA assays, but as more than 50% of anti-HCV positive persons will be HCV core antigen positive, HCV core antigen testing can be a cost effective and reflex test to confirm HCV infection in anti-HCV positive individuals and will be easier as it can be applied on the same platform. For treatment monitoring, more data need to be generated, but the early data available at present suggest that HCV core antigen may be an alternative to HCV RNA monitoring. With direct antivirals, HCV core antigen could even be superior to HCV RNA testing, as direct antivirals might already prevent virus formation when HCV core antigen is still produced and thereby correlates better with eventual viral clearance.

Citing Articles

Optical nanomaterial-based detection of biomarkers in liquid biopsy.

Kim Y, Rho W, Park S, Jun B J Hematol Oncol. 2024; 17(1):10.

PMID: 38486294 PMC: 10938695. DOI: 10.1186/s13045-024-01531-y.

903 Protein Saver cards: the best alternative for dried blood spot storage at room temperature for HCV RNA.

Arca-Lafuente S, Casanueva-Benitez C, Crespo-Bermejo C, Lara-Aguilar V, Martin-Carbonero L, de Los Santos I Sci Rep. 2022; 12(1):10124.

PMID: 35710721 PMC: 9203708. DOI: 10.1038/s41598-022-14375-8.

Hepatitis C core antigen test as an alternative for diagnosing HCV infection: mathematical model and cost-effectiveness analysis.

Sadeghimehr M, Bertisch B, Negro F, Butsashvili M, Shilton S, Tskhomelidze I PeerJ. 2021; 9:e11895.

PMID: 34595063 PMC: 8436958. DOI: 10.7717/peerj.11895.

Virus Detection: A Review of the Current and Emerging Molecular and Immunological Methods.

Cassedy A, Parle-McDermott A, OKennedy R Front Mol Biosci. 2021; 8:637559.

PMID: 33959631 PMC: 8093571. DOI: 10.3389/fmolb.2021.637559.

HCV core antigen plays an important role in the fight against HCV as an alternative to HCV-RNA detection.

Wang Y, Jie W, Ling J, Yuanshuai H J Clin Lab Anal. 2021; 35(6):e23755.

PMID: 33788295 PMC: 8183919. DOI: 10.1002/jcla.23755.

References

Morota K, Fujinami R, Kinukawa H, Machida T, Ohno K, Saegusa H . A new sensitive and automated chemiluminescent microparticle immunoassay for quantitative determination of hepatitis C virus core antigen. J Virol Methods. 2009; 157(1):8-14. DOI: 10.1016/j.jviromet.2008.12.009. View

Loggi E, Cursaro C, Scuteri A, Grandini E, Panno A, Galli S . Patterns of HCV-RNA and HCV core antigen in the early monitoring of standard treatment for chronic hepatitis C. J Clin Virol. 2012; 56(3):207-11. DOI: 10.1016/j.jcv.2012.11.012. View

Mederacke I, Wedemeyer H, Ciesek S, Steinmann E, Raupach R, Wursthorn K . Performance and clinical utility of a novel fully automated quantitative HCV-core antigen assay. J Clin Virol. 2009; 46(3):210-5. DOI: 10.1016/j.jcv.2009.08.014. View

Fujino T, Nakamuta M, Aoyagi Y, Fukuizumi K, Takemoto R, Yoshimoto T . Early decline of the HCV core antigen can predict SVR in patients with HCV treated by Pegylated interferon plus ribavirin combination therapy. J Dig Dis. 2009; 10(1):21-5. DOI: 10.1111/j.1751-2980.2008.00358.x. View

Vermehren J, Susser S, Berger A, Perner D, Peiffer K, Allwinn R . Clinical utility of the ARCHITECT HCV Ag assay for early treatment monitoring in patients with chronic hepatitis C genotype 1 infection. J Clin Virol. 2012; 55(1):17-22. DOI: 10.1016/j.jcv.2012.05.008. View

Matsui K, Iwabuchi S, Shimizu H, Yoshida A, Fujikawa T, Takatsuka K . Two week induction of interferon-beta followed by pegylated interferon alpha-2b and ribavirin for chronic infection with hepatitis C. Hepatol Res. 2010; 40(8):757-62. DOI: 10.1111/j.1872-034X.2010.00669.x. View

Tedder R, Tuke P, Wallis N, Wright M, Nicholson L, Grant P . Therapy-induced clearance of HCV core antigen from plasma predicts an end of treatment viral response. J Viral Hepat. 2012; 20(1):65-71. DOI: 10.1111/j.1365-2893.2012.01630.x. View

Murayama A, Sugiyama N, Watashi K, Masaki T, Suzuki R, Aizaki H . Japanese reference panel of blood specimens for evaluation of hepatitis C virus RNA and core antigen quantitative assays. J Clin Microbiol. 2012; 50(6):1943-9. PMC: 3372108. DOI: 10.1128/JCM.00487-12. View

Zuckerman A . The elusive hepatitis C virus. BMJ. 1989; 299(6704):871-3. PMC: 1837768. DOI: 10.1136/bmj.299.6704.871. View

10.

Mederacke I, Potthoff A, Meyer-Olson D, Meier M, Raupach R, Manns M . HCV core antigen testing in HIV- and HBV-coinfected patients, and in HCV-infected patients on hemodialysis. J Clin Virol. 2011; 53(2):110-5. DOI: 10.1016/j.jcv.2011.11.009. View

11.

Shouval D . Focus: quantitative HBsAg measurement as a new surrogate marker for assessment of hepatic fibrosis in HBeAg+ chronic hepatitis B. J Hepatol. 2013; 58(6):1063-4. DOI: 10.1016/j.jhep.2013.03.002. View

12.

Ottiger C, Gygli N, Huber A . Detection limit of architect hepatitis C core antigen assay in correlation with HCV RNA, and renewed confirmation algorithm for reactive anti-HCV samples. J Clin Virol. 2013; 58(3):535-40. DOI: 10.1016/j.jcv.2013.08.028. View

13.

Pradat P, Chossegros P, Bailly F, Pontisso P, Saracco G, Sauleda S . Comparison between three quantitative assays in patients with chronic hepatitis C and their relevance in the prediction of response to therapy. J Viral Hepat. 2000; 7(3):203-10. DOI: 10.1046/j.1365-2893.2000.00224.x. View

14.

Durante-Mangoni E, Vallefuoco L, Sorrentino R, Iossa D, Perna E, Molaro R . Clinico-pathological significance of hepatitis C virus core antigen levels in chronic infection. J Med Virol. 2013; 85(11):1913-8. DOI: 10.1002/jmv.23672. View

15.

Wada Y, Tamai H, Uno A, Kawashima A, Shingaki N, Mori Y . Prediction of efficacy to pegylated interferon-α-2b plus ribavirin in patients with genotype 2 hepatitis C virus using viral response within 2 weeks. Hepatol Res. 2013; 44(2):179-86. DOI: 10.1111/hepr.12101. View

16.

Kuo Y, Chang K, Wang J, Tsai P, Hung S, Hung C . Is hepatitis C virus core antigen an adequate marker for community screening?. J Clin Microbiol. 2012; 50(6):1989-93. PMC: 3372126. DOI: 10.1128/JCM.05175-11. View

17.

Moini M, Ziyaeyan M, Aghaei S, Sagheb M, Taghavi S, Moeini M . Hepatitis C virus (HCV) Infection Rate among Seronegative Hemodialysis Patients Screened by Two Methods; HCV Core Antigen and Polymerase Chain Reaction. Hepat Mon. 2013; 13(6):e9147. PMC: 3768235. DOI: 10.5812/hepatmon.9147. View

18.

Fytili P, Tiemann C, Wang C, Schulz S, Schaffer S, Manns M . Frequency of very low HCV viremia detected by a highly sensitive HCV-RNA assay. J Clin Virol. 2007; 39(4):308-11. DOI: 10.1016/j.jcv.2007.05.007. View

19.

Tillmann H, Wiegand J, Glomb I, Jelineck A, Picchio G, Wedemeyer H . Diagnostic algorithm for chronic hepatitis C virus infection: role of the new HCV-core antigen assay. Z Gastroenterol. 2005; 43(1):11-6. DOI: 10.1055/s-2004-813429. View

20.

Pas S, Molenkamp R, Schinkel J, Rebers S, Copra C, Seven-Deniz S . Performance evaluation of the new Roche cobas AmpliPrep/cobas TaqMan HCV test, version 2.0, for detection and quantification of hepatitis C virus RNA. J Clin Microbiol. 2012; 51(1):238-42. PMC: 3536185. DOI: 10.1128/JCM.01729-12. View